Oruka Therapeutics
ORKA
255 hedge funds and large institutions have $7.05B invested in Oruka Therapeutics in 2026 Q2 according to their latest regulatory filings, with 101 funds opening new positions, 94 increasing their positions, 45 reducing their positions, and 27 closing their positions.
274% more first-time investments, than exits
New positions opened: 101 | Existing positions closed: 27
176% more capital invested
Capital invested by funds: $2.55B → $7.05B (+$4.5B)
109% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 45
75% more funds holding in top 10
Funds holding in top 10: 8 → 14 (+6)
39% more funds holding
Funds holding: 184 → 255 (+71)
21% more call options, than puts
Call options by funds: $18.3M | Put options by funds: $15.1M
17.9% more ownership
Funds ownership: 105% → 122.9% (+18%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$227M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$108M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$104M |
| 4 |
BlackRock
New York
|
+$97.5M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$76.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$77.5M |
| 2 |
Mercer Global Advisors
Denver,
Colorado
|
-$39.4M |
| 3 |
SOCM
SR One Capital Management
Wayne,
Pennsylvania
|
-$21.1M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$19.3M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$11.9M |
ORKA Hedge Fund Activity: Q2 2026 in Review
255 of the 8,299 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q2 2026, worth a combined $7.05B — up 176% from $2.55B a quarter earlier.
Buyers outnumbered sellers: 101 funds opened new ORKA positions and 27 closed out — a net gain of 74 holders — while 94 added to existing stakes and 45 trimmed.
The largest buyer was Capital World Investors, opening a new position worth an estimated $227M. The largest seller was Viking Global Investors, cutting an estimated $77.5M.
- 255 institutional investors held Oruka Therapeutics (ORKA) as of Q2 2026, up from 184 in Q1 2026.
- Funds reported $7.05B of Oruka Therapeutics stock for Q2 2026, up 176% quarter-over-quarter.
- 101 funds opened new Oruka Therapeutics positions in Q2 2026 and 27 closed out, a net change of +74 holders.
- The largest Oruka Therapeutics buyer in Q2 2026 was Capital World Investors, an estimated $227M added.
- The largest Oruka Therapeutics seller in Q2 2026 was Viking Global Investors, an estimated $77.5M sold.
Based on aggregated 13F filings for Q2 2026.